Immunovant is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for autoimmune diseases. Its lead drug, batoclimab, is a fully human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor. It is in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease and has completed Phase II clinical trials for warm autoimmune hemolytic anemia. The company was incorporated in 2018 and is a subsidiary of Roivant Sciences Ltd.